Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.110
-0.050 (-4.31%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Lineage Cell Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.50. The average 1-year stock price forecast is 395.50% higher than the current stock price, while the lowest is $3.00 (+170.27%) and the highest is $9.00 (+710.81%).
Price Target: $5.50 (+395.50%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $3 | Buy | Maintains | $3 | +170.27% | Aug 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $9 | Buy | Maintains | $9 | +710.81% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 → $9 | Buy | Reiterates | $7 → $9 | +710.81% | Aug 7, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 15, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $3 → $4 | Buy | Maintains | $3 → $4 | +260.36% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
19.61M
from 14.56M
Increased by 34.73%
Revenue Next Year
19.64M
from 19.61M
Increased by 0.15%
EPS This Year
-0.05
from -0.22
EPS Next Year
-0.10
from -0.05
EPS and Forward PE are based on non-GAAP adjusted numbers.